Wikipedia

Cannabis use and trauma

Trauma contributed to promoting the use and potential abuse of cannabis.[1] Conversely, cannabis use has been associated with the intensity of trauma and PTSD symptoms.[2][3] While evidence of efficacious use of cannabis is growing in novelty, it is not currently recommended.[4][5]

Frequency and intensity of symptoms

edit

Individuals who have traumatic experiences have been found to have increased overall cannabis use and higher instances of cannabis use disorder (CUD), suggestive of problematic cannabis use.[6]  For example, veterans who identify as medicinal users have been shown to have a higher association with combat exposure, trauma related symptoms, and arousal when cued to situations, as well as overall cannabis use.[7]

Despite increased cannabis use in those with PTSD symptoms, a National Epidemiological Study with thousands of  participants based in the United States indicated lifetime PTSD was a weak predictor of lifetime cannabis use.[8][9][10] However, this study affirmed that for individuals who endorse cannabis use and trauma exposure, they are likely to have concurrent PTSD and CUD symptoms.[8][9][11] The strength of the association between heavy PTSD symptoms and CUD was stronger than that of CUD and other psychological disorders, namely depression, general and social anxiety, panic disorder, alcohol dependence, and personality disorders.[8] It is worth noting that this was done with older DSM-IV criteria, rather than the most current DSM-V, suggestive of possible shifts in diagnostic criteria used to gauge psychological and substance-related disorders.

Trauma as a motive

edit

High use of cannabis has been associated with coping motives in medicinal cannabis users with PTSD symptoms.[2] In a longitudinal study of American female twins, trauma and psychological symptoms were significant predictors for cannabis initiation and cannabis use disorder (CUD).[12][13] Individuals with higher levels of life-threatening events, injury, or experiences of death were also more likely to initiate cannabis use during the emerging adulthood phase, with sexual abuse predicting cannabis use initiation before the age of 15 in African American women.[13] In European-American women, sexual and physical abuse, as well as major depressive disorder (MDD) predicted age of cannabis initiation, with development of a CUD being predicting more specifically by MDD and physical abuse.[13] Those with sexual trauma who initiate cannabis use prior to the age of 16, are also more likely to develop psychosis.[14]

In women military veterans, a higher proportion of cannabis users who had experienced childhood and adult sexual trauma, had higher levels Post-Traumatic Stress Disorder (PTSD) diagnosis when compared to those with no drug use.[15]   When controlling for PTSD symptoms and demographic factors, regular cannabis use was still significantly related to sexual trauma.[15] For sexual minority women, have indicated higher cannabis use, coping motives, and post-traumatic stress symptoms than heterosexual women.[16][17] This may suggest that for women, trauma symptoms may be more severe for those who belong to a minority status, and the necessity to cope is often met by increasing cannabis use. These findings corroborate the idea that increased cannabis use can also be driven by minority stress, which has also been related to increased trauma.[18][19]

Viability and use of cannabis as treatment

edit

Emotion regulation and anxiety symptoms

edit

Tetrahydrocannabinol (THC)

edit

The psychoactive component of cannabis, tetrahydrocannabinol (THC) is not effective in treating emotion-regulation and anxiety-related symptoms.[20] Conversely, THC has been empirically related to an increase anxiety symptoms through impacts on neurological areas impacting serotonin, noradrenalin, GABA and glutamate.[20][21][22][23]

Cannabidiol (CBD)

edit

When using cannabidiol (CBD) results have indicated a weakened emotional response to traumatic memories.[24] This effect is attributed to the presence of endocannabinoid receptors in the limbic system, including the amygdala, and the hypothalamus that CBD may impact.[24][25][26][27] These components' effect likely leads to the reduction of neuroendocrine and behavioral stress responses.[24][28] Altogether, a cumulation of research indicates cannabinoids can help with fear extinction and combating depression.[24] However, further studies are needed to validate the therapeutic potential of cannabinoids for emotion dysregulation and anxiety symptoms associated with trauma.[24]

Sleep

edit

Tetrahydrocannabinol (THC)

edit

While the psychoactive component THC, has been shown to reduce time to get to sleep, studies indicate disrupted circadian rhythms when using THC.[29][30] Furthermore, THC is shown to have a quicker development of tolerance to sleep-inducing effects.[31] It is worth noting that synthetic THC has also shown the same effects of developed tolerance to sleep latency effects.[32]

However, individuals diagnosed with high PTSD scores have endorsed the use of medical cannabis for sleeping.[33][34] Studies have found some evidence for using Naboline, a synthetic version of THC, has proven effective for decreasing the frequency of PTSD related nightmares without developing long-term tolerance.[35][36][37][38]

Cannabinol (CBD)

edit

Novel research into cannabis suggests potential therapeutic effects of cannabinoids, specifically with higher doses of CBD, as opposed to lower doses, which can have an energizing effect.[30][39][40] In laboratory studies with rats, CBD has been shown to reduce sleep latency due to anxiety in REM sleep, with no negative changes to other aspects of sleep.[41][42]

References

edit
  1. ^ Hyman SM, Sinha R (June 2009). "Stress-related factors in cannabis use and misuse: implications for prevention and treatment". Journal of Substance Abuse Treatment. 36 (4): 400–13. doi:10.1016/j.jsat.2008.08.005. PMC 2696937. PMID 19004601.
  2. ^ a b Bonn-Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ (August 2007). "Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users". Journal of Traumatic Stress. 20 (4): 577–86. doi:10.1002/jts.20243. PMID 17721963.
  3. ^ Kevorkian S, Bonn-Miller MO, Belendiuk K, Carney DM, Roberson-Nay R, Berenz EC (September 2015). "Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample". Psychology of Addictive Behaviors. 29 (3): 633–8. doi:10.1037/adb0000110. PMC 4699174. PMID 26415060.
  4. ^ Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. (December 2019). "Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis". The Lancet. Psychiatry. 6 (12): 995–1010. doi:10.1016/s2215-0366(19)30401-8. PMC 6949116. PMID 31672337.
  5. ^ Dagan Y, Yager J (August 2020). "Cannabis and Complex Posttraumatic Stress Disorder: A Narrative Review With Considerations of Benefits and Harms". The Journal of Nervous and Mental Disease. 208 (8): 619–627. doi:10.1097/nmd.0000000000001172. PMID 32433200. S2CID 218766009.
  6. ^ Browne KC, Dolan M, Simpson TL, Fortney JC, Lehavot K (September 2018). "Regular past year cannabis use in women veterans and associations with sexual trauma". Addictive Behaviors. 84: 144–150. doi:10.1016/j.addbeh.2018.04.007. PMC 6716375. PMID 29684763.
  7. ^ Loflin M, Earleywine M, Bonn-Miller M (May 2017). "Medicinal versus recreational cannabis use: Patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD". Addictive Behaviors. 68: 18–23. doi:10.1016/j.addbeh.2017.01.008. PMID 28088054.
  8. ^ a b c Kevorkian S, Bonn-Miller MO, Belendiuk K, Carney DM, Roberson-Nay R, Berenz EC (September 2015). "Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample". Psychology of Addictive Behaviors. 29 (3): 633–8. doi:10.1037/adb0000110. PMC 4699174. PMID 26415060.
  9. ^ a b Buckner JD, Zvolensky MJ, Schmidt NB (November 2012). "Cannabis-related impairment and social anxiety: the roles of gender and cannabis use motives". Addictive Behaviors. 37 (11): 1294–7. doi:10.1016/j.addbeh.2012.06.013. PMID 22766487.
  10. ^ Buckner JD, Schmidt NB (November 2008). "Marijuana effect expectancies: relations to social anxiety and marijuana use problems". Addictive Behaviors. 33 (11): 1477–1483. doi:10.1016/j.addbeh.2008.06.017. PMC 2556243. PMID 18694625.
  11. ^ Zvolensky MJ, Bonn-Miller MO, Leyro TM, Johnson KA, Bernstein A (2010). Marijuana: An Overview of the Empirical Literature. New York, NY: Springer New York. pp. 445–461. ISBN 978-1-4419-0337-2. {{cite book}}: |work= ignored (help)
  12. ^ Diagnostic and statistical manual of mental disorders : DSM-5. American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. (Fifth ed.). Arlington, VA. 2013. ISBN 978-0-89042-559-6. OCLC 847226928.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
  13. ^ a b c Werner KB, McCutcheon VV, Agrawal A, Sartor CE, Nelson EC, Heath AC, Bucholz KK (May 2016). "The association of specific traumatic experiences with cannabis initiation and transition to problem use: Differences between African-American and European-American women". Drug and Alcohol Dependence. 162: 162–9. doi:10.1016/j.drugalcdep.2016.03.003. PMC 4833569. PMID 27012434.
  14. ^ Houston JE, Murphy J, Shevlin M, Adamson G (November 2011). "Cannabis use and psychosis: re-visiting the role of childhood trauma". Psychological Medicine. 41 (11): 2339–48. doi:10.1017/S0033291711000559. PMID 21557896. S2CID 32270892.
  15. ^ a b Browne KC, Dolan M, Simpson TL, Fortney JC, Lehavot K (September 2018). "Regular past year cannabis use in women veterans and associations with sexual trauma". Addictive Behaviors. 84: 144–150. doi:10.1016/j.addbeh.2018.04.007. PMC 6716375. PMID 29684763.
  16. ^ Walukevich-Dienst K, Dylanne Twitty T, Buckner JD (May 2019). "Sexual minority women and Cannabis use: The serial impact of PTSD symptom severity and coping motives". Addictive Behaviors. 92: 1–5. doi:10.1016/j.addbeh.2018.12.012. PMID 30553032. S2CID 56172257.
  17. ^ Dworkin ER, Kaysen D, Bedard-Gilligan M, Rhew IC, Lee CM (November 2017). "Daily-level associations between PTSD and cannabis use among young sexual minority women". Addictive Behaviors. 74: 118–121. doi:10.1016/j.addbeh.2017.06.007. PMC 5538382. PMID 28618391.
  18. ^ Gonzalez CA, Gallego JD, Bockting WO (August 2017). "Demographic Characteristics, Components of Sexuality and Gender, and Minority Stress and Their Associations to Excessive Alcohol, Cannabis, and Illicit (Noncannabis) Drug Use Among a Large Sample of Transgender People in the United States". The Journal of Primary Prevention. 38 (4): 419–445. doi:10.1007/s10935-017-0469-4. PMC 5516932. PMID 28405831.
  19. ^ Goldbach JT, Schrager SM, Dunlap SL, Holloway IW (February 2015). "The application of minority stress theory to marijuana use among sexual minority adolescents". Substance Use & Misuse. 50 (3): 366–75. doi:10.3109/10826084.2014.980958. PMID 25493644. S2CID 23419207.
  20. ^ a b Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P (October 2009). "Cannabis and anxiety: a critical review of the evidence". Human Psychopharmacology. 24 (7): 515–23. doi:10.1002/hup.1048. PMID 19693792. S2CID 13544234.
  21. ^ Braida D, Limonta V, Malabarba L, Zani A, Sala M (January 2007). "5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats". European Journal of Pharmacology. 555 (2–3): 156–63. doi:10.1016/j.ejphar.2006.10.038. PMID 17116299.
  22. ^ Degenhardt L, Hall W, Lynskey M (November 2003). "Exploring the association between cannabis use and depression". Addiction. 98 (11): 1493–504. doi:10.1046/j.1360-0443.2003.00437.x. PMID 14616175.
  23. ^ Pertwee RG (January 2008). "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin". British Journal of Pharmacology. 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.
  24. ^ a b c d e Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH (2012-06-26). "Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence". Drug Testing and Analysis. 4 (7–8): 649–59. doi:10.1002/dta.1377. PMID 22736575.
  25. ^ Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, Freund TF (December 2001). "Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission". The Journal of Neuroscience. 21 (23): 9506–18. doi:10.1523/jneurosci.21-23-09506.2001. PMC 6763903. PMID 11717385.
  26. ^ Walker JM, Huang SM (2002). "Cannabinoid analgesia". Pharmacology & Therapeutics. 95 (2): 127–135. doi:10.1016/S0163-7258(02)00252-8. PMID 12182960.
  27. ^ Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yücel M (September 2010). "Structural MRI findings in long-term cannabis users: what do we know?". Substance Use & Misuse. 45 (11): 1787–808. doi:10.3109/10826084.2010.482443. PMID 20590400. S2CID 22127231.
  28. ^ Jacobson L, Sapolsky R (May 1991). "The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis". Endocrine Reviews. 12 (2): 118–34. doi:10.1210/edrv-12-2-118. PMID 2070776.
  29. ^ Perron RR, Tyson RL, Sutherland GR (December 2001). "Delta9 -tetrahydrocannabinol increases brain temperature and inverts circadian rhythms". NeuroReport. 12 (17): 3791–4. doi:10.1097/00001756-200112040-00038. PMID 11726796. S2CID 25466602.
  30. ^ a b Babson KA, Sottile J, Morabito D (April 2017). "Cannabis, Cannabinoids, and Sleep: a Review of the Literature". Current Psychiatry Reports. 19 (4): 23. doi:10.1007/s11920-017-0775-9. PMID 28349316. S2CID 7429763.
  31. ^ Vaughn S, Cirino PT, Wanzek J, Wexler J, Fletcher JM, Denton CD, et al. (2010-03-01). "Response to Intervention for Middle School Students With Reading Difficulties: Effects of a Primary and Secondary Intervention". School Psychology Review. 39 (1): 3–21. doi:10.1080/02796015.2010.12087786. PMC 3072689. PMID 21479079.
  32. ^ Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, et al. (2013-01-01). "Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers". Journal of Analytical Toxicology. 37 (1): 11–6. doi:10.1093/jat/bks081. PMC 3584989. PMID 23074216.
  33. ^ Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA (January 2014). "Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users". The American Journal of Drug and Alcohol Abuse. 40 (1): 23–30. doi:10.3109/00952990.2013.821477. PMID 24205805. S2CID 8988512.
  34. ^ Metrik J, Jackson K, Bassett SS, Zvolensky MJ, Seal K, Borsari B (November 2016). "The mediating roles of coping, sleep, and anxiety motives in cannabis use and problems among returning veterans with PTSD and MDD". Psychology of Addictive Behaviors. 30 (7): 743–754. doi:10.1037/adb0000210. PMC 5218528. PMID 27786514.
  35. ^ Cameron C, Watson D, Robinson J (October 2014). "Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation". Journal of Clinical Psychopharmacology. 34 (5): 559–64. doi:10.1097/jcp.0000000000000180. PMC 4165471. PMID 24987795.
  36. ^ Fraser GA (2009). "The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)". CNS Neuroscience & Therapeutics. 15 (1): 84–8. doi:10.1111/j.1755-5949.2008.00071.x. PMC 6494011. PMID 19228182.
  37. ^ Jetly R, Heber A, Fraser G, Boisvert D (January 2015). "The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study". Psychoneuroendocrinology. 51: 585–8. doi:10.1016/j.psyneuen.2014.11.002. PMID 25467221. S2CID 29692607.
  38. ^ Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A (August 2014). "Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder". Clinical Drug Investigation. 34 (8): 587–91. doi:10.1007/s40261-014-0212-3. PMID 24935052. S2CID 4881658.
  39. ^ Carlini EA, Cunha JM (1981-08-09). "Hypnotic and antiepileptic effects of cannabidiol". Journal of Clinical Pharmacology. 21 (S1): 417S–427S. doi:10.1002/j.1552-4604.1981.tb02622.x. PMID 7028792. S2CID 7372390.
  40. ^ Nicholson AN, Turner C, Stone BM, Robson PJ (June 2004). "Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults". Journal of Clinical Psychopharmacology. 24 (3): 305–13. doi:10.1097/01.jcp.0000125688.05091.8f. PMID 15118485. S2CID 4846127.
  41. ^ Hsiao YT, Yi PL, Li CL, Chang FC (January 2012). "Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats". Neuropharmacology. Anxiety and Depression. 62 (1): 373–84. doi:10.1016/j.neuropharm.2011.08.013. PMID 21867717. S2CID 20340120.
  42. ^ Chagas MH, Crippa JA, Zuardi AW, Hallak JE, Machado-de-Sousa JP, Hirotsu C, et al. (March 2013). "Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats". Journal of Psychopharmacology. 27 (3): 312–6. doi:10.1177/0269881112474524. PMID 23343597. S2CID 5125324.
Retrieved from "https://en.wiki.x.io/w/index.php?title=Cannabis_use_and_trauma&oldid=1247546878"